Literature DB >> 20862596

Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection.

Kojun Okamoto1, Isamu Koyama, Mitsuo Miyazawa, Yasuko Toshimitsu, Masayasu Aikawa, Katsuya Okada, Etsuko Imabayashi, Hiroshi Matsuda.   

Abstract

BACKGROUND: An important step in deciding the treatment strategy for pancreatic cancer is to preoperatively predict the possibility of early recurrence. We reviewed whether 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) before pancreatic cancer resection could predict tumor recurrence in the early postoperative period.
METHODS: FDG-PET/CT was performed preoperatively on 56 patients with pancreatic cancer. The maximum standardized uptake (SUV(max)) values obtained by FDG-PET/CT were compared between two groups: patients with and without recurrence within the first 6 postoperative months. SUV(max) analyses were also performed to determine whether age, sex, CA 19-9 values, the operative method, and portal vein resection were also predictive of recurrence within less than 6 months after tumor resection.
RESULTS: The median SUV(max) values of the recurrence group and no-recurrence group were 7.9 and 4.2, respectively (P = 0.0042). The SUV(max) was the only risk factor for recurrence in the first 6 postoperative months identified by multivariate analysis (P = 0.0062).
CONCLUSIONS: Preoperative SUV(max) was higher in the recurrence group during the early postoperative period, and a high SUV(max) was a risk factor for early postoperative recurrence. Based on these results, we conclude that FDG-PET/CT is predictive of the recurrence of pancreatic cancer in the early postoperative period.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20862596     DOI: 10.1007/s10147-010-0124-z

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  28 in total

1.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

2.  Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake.

Authors:  Jong Doo Lee; Woo Ick Yang; Young Nyun Park; Kyung Sik Kim; Jin Sub Choi; Mijin Yun; Dooheun Ko; Tae-Sung Kim; Arthur E H Cho; Hye Mi Kim; Kwang-Hyub Han; Seung-Soon Im; Yong-Ho Ahn; Chang Woon Choi; Jeon Han Park
Journal:  J Nucl Med       Date:  2005-10       Impact factor: 10.057

3.  Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study.

Authors:  T Higashi; N Tamaki; T Honda; T Torizuka; T Kimura; T Inokuma; G Ohshio; R Hosotani; M Imamura; J Konishi
Journal:  J Nucl Med       Date:  1997-09       Impact factor: 10.057

4.  Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.

Authors:  Ralf Wilkowski; Martin Thoma; Christiane Bruns; Andreas Wagner; Volker Heinemann
Journal:  JOP       Date:  2006-07-10

5.  A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer.

Authors:  Masayuki Imamura; Ryuichiro Doi; Toshihide Imaizumi; Akihiro Funakoshi; Hideyuki Wakasugi; Makoto Sunamura; Yoshiro Ogata; Shoichi Hishinuma; Takehide Asano; Takashi Aikou; Ryo Hosotani; Shunzo Maetani
Journal:  Surgery       Date:  2004-11       Impact factor: 3.982

6.  Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial.

Authors:  Ryuichiro Doi; Masayuki Imamura; Ryo Hosotani; Toshihide Imaizumi; Takashi Hatori; Ken Takasaki; Akihiro Funakoshi; Hideyuki Wakasugi; Takehide Asano; Shoichi Hishinuma; Yoshiro Ogata; Makoto Sunamura; Koji Yamaguchi; Masao Tanaka; Sonshin Takao; Takashi Aikou; Koichi Hirata; Hiroyuki Maguchi; Koichi Aiura; Tatsuya Aoki; Akira Kakita; Makoto Sasaki; Masahiko Ozaki; Satoru Matsusue; Shunichi Higashide; Hideki Noda; Seiyo Ikeda; Shunzo Maetani; Shigeaki Yoshida
Journal:  Surg Today       Date:  2008-10-29       Impact factor: 2.549

Review 7.  Preoperative evaluation of pancreatic adenocarcinoma.

Authors:  Colin M Parsons; Julie L Sutcliffe; Richard J Bold
Journal:  J Hepatobiliary Pancreat Surg       Date:  2008-08-01

8.  Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection.

Authors:  Robert J Downey; Timothy Akhurst; Mithat Gonen; Alain Vincent; Manjit S Bains; Steven Larson; Valerie Rusch
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

9.  Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis.

Authors:  Timothy N Showalter; Atul S Rao; P Rani Anne; Francis E Rosato; Ernest L Rosato; Jocelyn Andrel; Terry Hyslop; Xia Xu; Adam C Berger
Journal:  Ann Surg Oncol       Date:  2009-05-13       Impact factor: 5.344

10.  FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis.

Authors:  Mariëtte C A van Kouwen; Jan B M J Jansen; Harry van Goor; Steve de Castro; Wim J G Oyen; Joost P H Drenth
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-11-12       Impact factor: 9.236

View more
  15 in total

1.  The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients.

Authors:  Woohyun Jung; Jin-Young Jang; Mee Joo Kang; Ye Rim Chang; Yong Chan Shin; Jihoon Chang; Sun-Whe Kim
Journal:  HPB (Oxford)       Date:  2015-12-21       Impact factor: 3.647

Review 2.  The role of ¹⁸F-FDG PET imaging in upper gastrointestinal malignancies.

Authors:  Tong Dai; Elizabeta Popa; Manish A Shah
Journal:  Curr Treat Options Oncol       Date:  2014-09

3.  Multimodality treatment of recurrent pancreatic cancer: Mith or reality?

Authors:  Cosimo Sperti; Lucia Moletta; Stefano Merigliano
Journal:  World J Gastrointest Oncol       Date:  2015-12-15

4.  State-of-the-art PET/CT of the pancreas: current role and emerging indications.

Authors:  Dushyant V Sahani; Pietro A Bonaffini; Onofrio A Catalano; Alexander R Guimaraes; Michael A Blake
Journal:  Radiographics       Date:  2012 Jul-Aug       Impact factor: 5.333

Review 5.  Beyond Correlations, Sensitivities, and Specificities: A Roadmap for Demonstrating Utility of Advanced Imaging in Oncology Treatment and Clinical Trial Design.

Authors:  Erich P Huang; Frank I Lin; Lalitha K Shankar
Journal:  Acad Radiol       Date:  2017-04-26       Impact factor: 3.173

6.  Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer.

Authors:  Hirotada Kittaka; Hidenori Takahashi; Hiroaki Ohigashi; Kunihito Gotoh; Terumasa Yamada; Yasuhiko Tomita; Yoshihisa Hasegawa; Masahiko Yano; Osamu Ishikawa
Journal:  World J Surg       Date:  2013-01       Impact factor: 3.352

7.  Maximum standardized uptake value on 18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography and glucose transporter-1 expression correlates with survival in invasive ductal carcinoma of the pancreas.

Authors:  Yuhei Kitasato; Masafumi Yasunaga; Koji Okuda; Hisafumi Kinoshita; Hiroyuki Tanaka; Yoshinobu Okabe; Akihiko Kawahara; Masayoshi Kage; Hayato Kaida; Masatoshi Ishibashi
Journal:  Pancreas       Date:  2014-10       Impact factor: 3.327

Review 8.  Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: A systematic review and meta-analysis.

Authors:  Dongyong Zhu; Lisha Wang; Hanfei Zhang; Jie Chen; Yanfang Wang; Sama Byanju; Meiyan Liao
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

9.  [18F]FMISO PET/CT as a preoperative prognostic factor in patients with pancreatic cancer.

Authors:  Tomohiko Yamane; Masayasu Aikawa; Masanori Yasuda; Kenji Fukushima; Akira Seto; Koujun Okamoto; Isamu Koyama; Ichiei Kuji
Journal:  EJNMMI Res       Date:  2019-05-09       Impact factor: 3.138

10.  Current state of surgical management of pancreatic cancer.

Authors:  Thilo Hackert; Markus W Büchler; Jens Werner
Journal:  Cancers (Basel)       Date:  2011-03-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.